{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T14:39:36Z","timestamp":1648823976597},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,5,22]],"date-time":"2013-05-22T00:00:00Z","timestamp":1369180800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s11886-013-0378-y","type":"journal-article","created":{"date-parts":[[2013,5,20]],"date-time":"2013-05-20T22:39:39Z","timestamp":1369089579000},"source":"Crossref","is-referenced-by-count":0,"title":["Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Andrew","family":"Krasner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,22]]},"reference":[{"issue":"Suppl","key":"378_CR1","first-page":"e531S","volume":"141","author":"JJ You","year":"2012","unstructured":"You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl):e531S\u201375S.","journal-title":"Chest"},{"issue":"60","key":"378_CR2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2012.06.004","volume":"14","author":"H Jneid","year":"2012","unstructured":"Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF\/AHA focused update of the guideline for the management of patients with unstable angina\/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update). J Am Coll Cardiol. 2012;14(60):645\u201381.","journal-title":"J Am Coll Cardiol"},{"key":"378_CR3","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.amjcard.2008.08.021","volume":"102","author":"R Rossini","year":"2008","unstructured":"Rossini R, Musumeci G, Lettieri C, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol. 2008;102:1618\u201323.","journal-title":"Am J Cardiol"},{"key":"378_CR4","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1540-8183.2009.00468.x","volume":"22","author":"A Rubboli","year":"2009","unstructured":"Rubboli A, Colletta M, Valencia J, et al. WARfarin, Coronary STENTing (WAR-STENT) Study Group. Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting. J Interv Cardiol. 2009;22:390\u20137.","journal-title":"J Interv Cardiol"},{"key":"378_CR5","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1161\/CIR.0b013e318214876d","volume":"123","author":"V Fuster","year":"2011","unstructured":"Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF\/AHA\/HRS Focused update incorporated into the ACC\/AHA\/ESC 2006 Guidelines for the management of patients with atrial fibrillation. Circulation. 2011;123:e269\u2013367.","journal-title":"Circulation"},{"key":"378_CR6","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","volume":"31","author":"AJ Camm","year":"2010","unstructured":"Camm AJ, Kirchhof P, Lip GY, et al. European Society of Cardiology, European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation. Eur Heart J. 2010;31:2369\u2013429.","journal-title":"Eur Heart J."},{"key":"378_CR7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.clinthera.2012.01.019","volume":"34","author":"KM Dell","year":"2012","unstructured":"Dell KM, Igawa D, Hsin J, et al. New oral anticoagulants for atrial fFibrillation: a review of clinical trials. Clin Ther. 2012;34:894\u2013901.","journal-title":"Clin Ther"},{"key":"378_CR8","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351.","journal-title":"N Engl J Med"},{"key":"378_CR9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban vs warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med"},{"key":"378_CR10","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, et al. Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med"},{"key":"378_CR11","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/eurheartj\/ehq117","volume":"31","author":"GY Lip","year":"2010","unstructured":"Lip GY, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing coronary stenting: Executive Summary. Eur Heart J. 2010;31:1311\u20138.","journal-title":"Eur Heart J."},{"key":"378_CR12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/CIRCINTERVENTIONS.111.965186","volume":"4","author":"DP Faxon","year":"2011","unstructured":"Faxon DP, Eikelboom JW, Berger PB, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stentingA North-American perspective. Circ Cardiovasc Interv. 2011;4:522\u201334.","journal-title":"Circ Cardiovasc Interv."},{"key":"378_CR13","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","volume":"360","author":"S Connolly","year":"2009","unstructured":"\u2022\u2022 Connolly S, Pogue J, Hart R, et al. ACTIVE Intvestigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066\u201378. This study supports the view that dual antiplatelet therapy has greater efficacy against stroke than aspirin alone in patient with atrial fibrillation.","journal-title":"N Engl J Med."},{"key":"378_CR14","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","volume":"367","author":"S Connolly","year":"2006","unstructured":"Connolly S, Pogue J, Hart R, et al. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin vs oral anticoagulation for atrial fibrillation (ACTIVE W): a randomized controlled trial. Lancet. 2006;367:1903\u201312.","journal-title":"Lancet"},{"key":"378_CR15","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ahj.2006.06.024","volume":"152","author":"GC Flaker","year":"2006","unstructured":"Flaker GC, Gruber M, Connolly SJ, et al. SPORTIF Investigators. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J. 2006;152:967\u201373.","journal-title":"Am Heart J."},{"key":"378_CR16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000047711","volume":"12","author":"P Lechat","year":"2001","unstructured":"Lechat P, Lardoux H, Mallet A, et al. FFAACS (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontan\u00e9) Investigators. Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fi brillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontan\u00e9; FFAACS). Cerebrovasc Dis. 2001;12:245\u201352.","journal-title":"Cerebrovasc Dis"},{"key":"378_CR17","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1253\/circj.CJ-09-0880","volume":"74","author":"F Gao","year":"2010","unstructured":"Gao F, Zhou YJ, Wang ZJ, et al. Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation. Circ J. 2010;74:701\u20138.","journal-title":"Circ J"},{"key":"378_CR18","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jacc.2004.09.079","volume":"45","author":"AT Ong","year":"2005","unstructured":"Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol. 2005;45:947\u201353.","journal-title":"J Am Coll Cardiol"},{"key":"378_CR19","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jacc.2007.10.057","volume":"51","author":"JM Torre-Hern\u00e1ndez de la","year":"2008","unstructured":"de la Torre-Hern\u00e1ndez JM, Alfonso F, Hern\u00e1ndez F, et al. ESTROFA Study Group. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpa\u00f1ol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol. 2008;51:986\u201390.","journal-title":"J Am Coll Cardiol"},{"key":"378_CR20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"SR Mehta","year":"2001","unstructured":"Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527\u201333.","journal-title":"Lancet"},{"key":"378_CR21","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","volume":"339","author":"MB Leon","year":"1998","unstructured":"Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665\u201371.","journal-title":"N Engl J Med."},{"key":"378_CR22","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","volume":"126","author":"M Lamberts","year":"2012","unstructured":"\u2022\u2022 Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126:1185\u201393. A nationwide registry of patients with AF admitted for MI or PCI that emphasizes the short and longer-term bleeding risk associated with TT.","journal-title":"Circulation."},{"key":"378_CR23","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJM199308193290802","volume":"329","author":"AG Turpie","year":"1993","unstructured":"Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med. 1993;329:524\u20139.","journal-title":"N Engl J Med"},{"key":"378_CR24","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/STROKEAHA.112.650614","volume":"43","author":"RG Hart","year":"2012","unstructured":"Hart RG, Diener H, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY Trial. Stroke. 2012;43:1511\u20137.","journal-title":"Stroke"},{"key":"378_CR25","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1161\/CIRCULATIONAHA.109.924944","volume":"121","author":"JS Paikin","year":"2010","unstructured":"Paikin JS, Wright DS, Crowther MA, et al. Trial antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation. 2010;121:2067\u201370.","journal-title":"Circulation"},{"key":"378_CR26","unstructured":"\u2022\u2022 DeWilde W, Oirbans T, Verheugt F, et al. The WOEST Trial: First randomized trial comparing two regimens with and without aspirin in patients on oral anticoagulant therapy undergoing coronary stenting. Hotline Session 3, European Society of Cardiology, Munich, Germany. August 28, 2012. This is the first randomized trial comparing patients on OAC undergoing PCI with clopidogrel alone or clopidogrel plus aspirin. The study showed that patients on triple therapy bled more and the rates of MI, target vessel revascularization, stroke, and stent thrombosis alone did not differ significantly between the groups."},{"key":"378_CR27","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","volume":"32","author":"J Oldgren","year":"2011","unstructured":"Oldgren J, Budaj A, Granger CB, et al. RE-DEEM Investigators. Dabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32:2781\u20139.","journal-title":"Eur Heart J."},{"key":"378_CR28","unstructured":"Dans AL, Connolly SJ, Br\u00fcchmann M, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin: a subgroup analysis from RE-LY. European Society of Cardiology, Paris, France. August, 2011: Session 709009\u2013709010; http:\/\/spo.escardio.org\/eslides\/view.aspx?eevtid=48&fp=1161 (accessed December 1, 2012)."},{"key":"378_CR29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","volume":"374","author":"JL Mega","year":"2009","unstructured":"Mega JL, Braunwald E, Mohanavelu S, et al. ATLAS ACS-TIMI 46 study group. Rivaroxaban vs placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomized, double-blind, phase II trial. Lancet. 2009;374:29\u201338.","journal-title":"Lancet"},{"key":"378_CR30","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","volume":"119","author":"JH Alexander","year":"2009","unstructured":"Alexander JH, Becker RC, Bhatt DL, et al. APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877\u201385.","journal-title":"Circulation"},{"key":"378_CR31","first-page":"699","volume":"365","author":"JH Alexander","year":"2011","unstructured":"\u2022\u2022 Alexander JH, Lopes RD, James S, et al. APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699\u2013708. This study found a dose dependent increase in clinically relevant bleeding in patients placed on apixaban along with antiplatelet therapy after ACS.","journal-title":"Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med."},{"key":"378_CR32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"\u2022\u2022 Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2\u2013TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9\u201319. This study shows that the 2.5 mg b.i.d. dose of rivaroxaban reduced the rates of death from cardiovascular causes and from any cause in patients with recent acute coronary syndrome receiving dual antiplatelet therapy.","journal-title":"N Engl J Med."},{"key":"378_CR33","doi-asserted-by":"crossref","unstructured":"Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. for the WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomized, controlled trial. Lancet. 2013 Feb 12. doi: 10.1016\/S0140-6736(12)62177-1 . [Epub ahead of print].","DOI":"10.1016\/S0140-6736(12)62177-1"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-013-0378-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-013-0378-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-013-0378-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T19:51:41Z","timestamp":1559418701000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-013-0378-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,22]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["378"],"URL":"https:\/\/doi.org\/10.1007\/s11886-013-0378-y","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,22]]},"article-number":"378"}}